Covered recipient · General Payments record
NICHOLAS JOHN VAN BENSCHOTEN
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2021–2024
$911.15
- Reported across 36 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $417.75 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $198.60 | 5 |
| Novo Nordisk AS | $64.07 | 4 |
| ABBVIE INC. | $60.38 | 3 |
| DEXCOM, INC. | $42.83 | 2 |
| DePuy Synthes Sales Inc. | $23.67 | 1 |
| Exact Sciences Corporation | $14.82 | 1 |
| Acerta Pharma LLC | $13.38 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $14.74 | 02/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106267612 | CMS |
| ABBVIE INC. | $27.33 | 07/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106267614 | CMS |
| ABBVIE INC. | $18.31 | 09/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106267616 | CMS |
| AstraZeneca Pharmaceuticals LP | $13.38 | 04/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104340582 | CMS |
| DePuy Synthes Sales Inc. | $23.67 | 07/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1077881132 | CMS |
| Dexcom, Inc. | $20.18 | 07/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153325645 | CMS |
| Dexcom, Inc. | $22.65 | 09/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153325647 | CMS |
| Exact Sciences Corporation | $14.82 | 02/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114938713 | CMS |
| Lilly USA, LLC | $23.72 | 01/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135177159 | CMS |
| Lilly USA, LLC | $20.92 | 02/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135231936 | CMS |
| Lilly USA, LLC | $122.78 | 04/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135249599 | CMS |
| Lilly USA, LLC | $9.57 | 07/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135231940 | CMS |
| Lilly USA, LLC | $21.61 | 08/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135177161 | CMS |
| Novo Nordisk Inc | $14.33 | 01/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097583790 | CMS |
| Novo Nordisk Inc | $13.34 | 05/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097519511 | CMS |
| Novo Nordisk Inc | $14.61 | 08/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097484960 | CMS |
| Novo Nordisk Inc | $21.79 | 12/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096837723 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.